Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.83 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP4X1 | Q8N118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898611 | 0.94 | PPARG (0.85) | PPARGPPARACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2901821 | 0.94 | PPARG (0.85) | PPARGPPARACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2903573 | 0.91 | PPARG (1.00) | PPARGPPARACYP2C9 | |
| SCHEMBL6417403 | 0.91 | PPARG (1.00) | PPARGPPARACYP2C9 | |
| SCHEMBL2901977 | 0.91 | PPARG (1.00) | PPARGPPARACYP2C9 | |
| SCHEMBL2898822 | 0.90 | PPARG (0.69) | PPARGPPARACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2896724 | 0.90 | PPARG (0.89) | PPARGPPARACYP2C9 | |
| SCHEMBL2896148 | 0.88 | PPARG (0.65) | PPARGPPARACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2903828 | 0.88 | PPARG (0.75) | PPARGPPARACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2898975 | 0.88 | PPARG (0.75) | PPARGPPARACYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | claimed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | claimed |
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
| WO-2004020408-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP1A2 456/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CYP1A2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.